There are a couple of valuation factors supporting the idea that Pfizer's stock is undervalued, starting with its ...

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...

Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...